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Introduction
With the advancement of technology and availability of mechanical
circulatory support (MCS) devices for the treatment of acute decompensated
systolic HF in the 21st century, the role of inotropes is becoming obsolete.
Medical therapy for acute decompensated heart failure (HF) has not changed
since 1960’s, we still use supplemental oxygen, diuretics, vasodilators and
inotropes to improve congestion, cardiac output, end organ perfusion and
symptoms related to elevate filling pressures1.
Despite demonstrated
improvements in hemodynamics, the uses of inotropes have not demonstrated
any improvements in mortality. Mechanical circulatory support (MCS) use is
growing rapidly in the USA, in patients with stage D HF both as destination
therapy and as a bridge to cardiac transplantation. In both, transplant-eligible
and non-transplant-eligible patients, improvement in end-organ perfusion,
functional capacity, quality of life and most importantly mortality have been
demonstrated. In this perspective paper we are going to discuss the current lack
of evidence for inotropic therapy and the evolving benefit of MCS in end-stage
systolic HF patients.

Not
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Inotropes in End-Stage HF
Advanced HF with cardiogenic shock, are syndromes characterized in many
patients by a reduction in myocardial contractile force. Medical therapy is still
considered the mainstay for acute decompensated HF. The guidelines
recommend diuretic therapy, which decreases intracardiac filling pressures and
relieve congestion 2-4 This has to be accompanied with medications favoring left
ventricular reverse remodeling such as angiotensin-converting enzyme inhibitors
(ACEI) 5, angiotensin receptors blockers6, beta blockers7, aldosterone blockers8,
and nitrate/hydralazine 9. As the disease progresses, compensatory mechanisms
fail, and cardiac output decreases (stage D HF).
Inotropic therapies are utilized to stabilize acute decompensated HF
patients with low cardiac output. The use of inotropes can be divided into three
distinct patterns of use: hospital admission for patients presenting with acute
decompensated HF and end organ involvement, intermittent home infusions
(several times per week at the infusion center), and continuous home infusion as
a bridge to cardiac transplantation or for palliation 10-12.
Inotropes have been used for more than fifty years and continues to be
the used in patients presenting with low perfusion state due to cardiogenic shock.
1
The Acute HF Global Survey of Standard Treatment (ALARM-HF) global survey
of 666 hospitals in nine countries showed that inotropes were used in 39% of all
admissions for acute HF13. Furthermore, in the mechanical circulatory support
(MCS) studies, 72% of patients in the medical arm and 65% of patients in the
ventricular assist device arm were on inotropes14. Inotropes successfully improve
cardiac hemodynamics and patients’ symptoms by increasing myocardial
contractility mainly by increasing intracellular calcium concentrations. Inotropes
are crucial in bridging selected patients to cardiac transplantation 15.
Despite improving hemodynamic compromise, inotropic agents are
accompanied by increased morbidity and mortality due to increased tachycardia
and myocardial oxygen consumption leading to arrhythmia, and myocardial
ischemia 16. This negative effect has been demonstrated in both the hospital and
outpatient setting.2 Beside digoxin, the current American College of
Cardiology/American Heart Association, European Society of Cardiology and
Heart Failure Society of America guidelines endorse that inotropic agents should
be reserved for patients presenting with acute decompensated HF and lowoutput states and reduced end-organ perfusion, who typically are admitted to an
intensive care unit 2-4. Furthermore, the ACCF/AHA guidelines state specifically
that use of parenteral inotropic agents in hospitalized patients without
documented severe systolic dysfunction, low blood pressure, or impaired
perfusion, and evidence of significantly depressed cardiac output, with or without
congestion, is potentially harmful. This is based on multiple studies showing
evidence for harm in patients with advanced HF 16.
Chronic HF patients who are not eligible for advanced therapies have
been shown to have poor survival when treated with inotropes 17,18. These finding
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are based on retrospective studies and post hoc analysis of prospective studies
16
. However, despite the reduced survival, many patients prefer improved quality
of life, even at the potential expense of a shorter survival. 18,19 The decision to
use inotropic therapy and the selection of inotropic agent should reflect the
realistic goals of therapy for the individual with HF. These goals should be
discussed in great detail with the patient and family.

Evidence is sufficient to link inotropes to increased mortality
Based on the current studies that showed increased mortality in patients
with advanced HF treated with inotropes, the use of inotropes should be limited
to patients with advanced HF who are not candidates to MCS or heart
transplantation. In the ADHERE (Acute Decompensated Heart Failure National
Registry) study17, Abraham et al. performed a retrospective analysis of
observational patient data from the ADHERE registry where they reviewed over
65,000 cases admitted for acute decompensated HF from 263 US hospitals
during October 2001 to July 2003 where they included patients whom had
received nitroglycerin, nesiritide, milrinone or dobutamine (n= 15,230) therapy
and assessed risk factor and propensity-adjusted odds ratios for in-hospital
mortality. What they demonstrated was that use of inotropes doubled the inhospital mortality compared to use of vasodilators; 12.3% and 13.9% for patients
receiving milrinone and dobutamine, respectively, compared to 4.7% and 7.1%
for patients receiving nitroglycerin and nesiritide, respectively. Moreover, they
also found that length of stay was longer compared to those on vasodilator
therapy, 10.9 and 10 days for patients receiving milrinone and dobutamine,
respectively, compared to 7.1 and 7.9 days for patients receiving nitroglycerin
and nesiritide, respectively.
Inotropic dependence is defined as the failure to wean from inotropes
because of imminent (minutes to hours) worsening of the patient’s clinical status
such that death appeared impending, and the patient is deemed highly unlikely to
survive inotrope withdrawal to permit hospital discharge 20. In other words,
withdrawal of inotropic support in this cohort of patients can be acutely lifethreatening 2,20.
Furthermore, in the OPTIME-CHF (Outcomes of a Prospective Trial of
Intravenous Milrinone for Exacerbations of Chronic HF) trial 21, Cuff et al.
demonstrated in this prospective study that intravenous (IV) milrinone used in
chronic HF patients, admitted for acute decompensated HF, increased morbidity
associated with hypotension and new atrial arrhythmias but no significant
difference in in-hospital mortality or 60-day mortality. As an extension of the
OPTIME-CHF trial, Felker et al. 22analyzed the interaction of the etiology of HF
(ischemic vs. non-ischemic) with IV milrinone and found that patients with
ischemic HF were not only hospitalized longer (13 days vs. 11.7 days) but also
had increased 60-day mortality (11.6% vs. 7.5%) compared to patients with nonischemic cardiomyopathy. In this study, 22% of patients were started on betablockers on admission. Thus, the “neutralizing” effect of beta-blockers for
milrinone infusion was suspected. A post-hoc analysis was done looking into the
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neutralizing effect of milrinone and showed decrease incidence of death or rehospitalization in non-ischemic group suggesting neutralizing effect. However,
the study had limitation since it was retrospective post-hoc analysis and authors
did not clarify the definition of ischemic cardiomyopathy. Furthermore, double the
patients in the non-ischemic cardiomyopathy group were lost to follow up 23.
In spite of increased mortality seen in the inpatient setting as seen in the
ADHERE study, the consideration of intermittent inotropic therapy has also been
studied in the outpatient setting. With a varying array of treatment regimens as
well as administration from daily to weekly regimens, some with concomitant use
of amiodarone as an antiarrhythmic, there has been some evidence of improved
symptoms, decreased hospitalization and short term mortality, but the studies
were small and observational in nature and failed to demonstrate “true” benefit of
intermittent inotropic therapy 18,24,25.

Inotropes Use in Palliative and Hospice Care
Due to lack of evidence for mortality benefit association with inotropes in
ADHF patients, inotropes were studies in hospice care and palliative care
settings. 20 In one prospective study, the author suggested that intermittent
infusion of intravenous inotropes is can modify end-stage HF symptoms, improve
functional class and may also facilitate better utilization of hospice and palliative
care resources among patients with end-stage heart. 26 The current HF
guidelines suggest that long-term, continuous intravenous inotropic support may
be considered as palliative therapy for symptom control in select patients with
stage D HF despite optimal medical therapy and device therapy who are not
eligible for either MCS or cardiac transplantation. 2

Mechanical Circulatory Assist Devices – A Game Changer in EndStage HF management
Prior to the advent of left ventricular assist devices (LVAD), patients with
end-stage HF who were ineligible for heart transplant did not have many options
except for palliative care or palliative inotropic therapy which was not a viable
long term treatment strategy. To evaluate the efficacy of LVADs, the REMATCH
(Randomized Evaluation of Mechanical Assistance for the Treatment of
Congestive HF) trial from May 1998 to July 2001 randomized 128 patients to
either LVAD or optimal medical therapy 14. Their findings were remarkable.
Survival at one year was 52% in the device group and 25% in the medical group.
The observed mortality of 75% at 1 year in the medical group approaches
mortality rates seen in pancreatic cancer. Of note, however, patients in the
device group were twice as likely to have a serious adverse effect, namely,
infection, bleeding or malfunction of device, but overall had improved quality of
life compared to medical group. Moreover, the INTrEPID (Investigation of Nontransplant Eligible Patients who are Inotropic Dependent) 27 trial which was a
prospective nonrandomized clinical trial comparing LVAD to optimal medical
therapy enrolled 55 patients between March 2000 and May 2003 who were
inotropic dependent, demonstrated that survival at 6 months was 46% in the
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device group and 22% in the medical group and survival at 1 year was 27% in
the device group and 11% in the medical group. Further, 85% of the LVAD
patients demonstrated either no symptoms or minimal HF symptoms compared
to the medical group, whom experienced no improvement in functional NYHA
class. Results of the REMATCH and INTrEPID trial demonstrated that patients
with end-stage HF have dismal survival rates on optimal medical therapy, but do
far much better with mechanical support as well as have improved quality of life.
With evidence of the benefits of mechanical support compared to
inotropic therapy for end-stage HF, it is essential to consider mechanical support
as the first line treatment in patients with end-stage HF, with inotropes being
reserved to acutely stabilize the patient as a bridge to MCS or for palliation.
Further, future research should not be directed to development of novel inotropic
agents as by definition any drug that increases myocardial contractility will result
in increase myocardial oxygen demand, which is associate with worse outcomes.
Medical therapy in end stage HF is obsolete and this is the era of mechanical
circulatory support. Although inotropes may be useful as a short-term strategy to
help temporize acute hemodynamic instability in cardiogenic shock, the clear
increase in mortality and morbidity with its use should be weighed against the
benefit of a more durable, long-term treatment strategy with mechanical assist
devices.
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